nodes	percent_of_prediction	percent_of_DWPC	metapath
Vardenafil—CYP3A4—Temozolomide—melanoma	0.0781	0.451	CbGbCtD
Vardenafil—PDE5A—clitoris—melanoma	0.0763	0.332	CbGeAlD
Vardenafil—PDE6G—optic choroid—melanoma	0.0521	0.227	CbGeAlD
Vardenafil—CYP3A4—Vemurafenib—melanoma	0.0428	0.247	CbGbCtD
Vardenafil—CYP3A5—Docetaxel—melanoma	0.0376	0.217	CbGbCtD
Vardenafil—CYP3A4—Docetaxel—melanoma	0.0147	0.0848	CbGbCtD
Vardenafil—PDE6H—eye—melanoma	0.0109	0.0475	CbGeAlD
Vardenafil—PDE6H—retina—melanoma	0.0108	0.0471	CbGeAlD
Vardenafil—PDE6G—eye—melanoma	0.0105	0.0457	CbGeAlD
Vardenafil—PDE6G—retina—melanoma	0.0104	0.0453	CbGeAlD
Vardenafil—PDE5A—endothelium—melanoma	0.00845	0.0368	CbGeAlD
Vardenafil—PDE5A—blood vessel—melanoma	0.00779	0.034	CbGeAlD
Vardenafil—PDE6H—head—melanoma	0.00619	0.027	CbGeAlD
Vardenafil—PDE6G—head—melanoma	0.00596	0.026	CbGeAlD
Vardenafil—PDE6G—lymph node—melanoma	0.00417	0.0182	CbGeAlD
Vardenafil—PDE5A—eye—melanoma	0.00415	0.0181	CbGeAlD
Vardenafil—PDE5A—retina—melanoma	0.00411	0.0179	CbGeAlD
Vardenafil—PDE10A—head—melanoma	0.00402	0.0175	CbGeAlD
Vardenafil—PDE1B—head—melanoma	0.00399	0.0174	CbGeAlD
Vardenafil—PDE10A—lymph node—melanoma	0.00282	0.0123	CbGeAlD
Vardenafil—PDE1B—lymph node—melanoma	0.00279	0.0122	CbGeAlD
Vardenafil—PDE5A—head—melanoma	0.00235	0.0103	CbGeAlD
Vardenafil—PDE5A—lymph node—melanoma	0.00165	0.00719	CbGeAlD
Vardenafil—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.00131	0.00456	CcSEcCtD
Vardenafil—Lacrimation increased—Docetaxel—melanoma	0.00131	0.00455	CcSEcCtD
Vardenafil—Face oedema—Temozolomide—melanoma	0.00127	0.00442	CcSEcCtD
Vardenafil—Anaphylactic shock—Vemurafenib—melanoma	0.00127	0.0044	CcSEcCtD
Vardenafil—Dysphagia—Dactinomycin—melanoma	0.00126	0.00437	CcSEcCtD
Vardenafil—Infection—Vemurafenib—melanoma	0.00126	0.00437	CcSEcCtD
Vardenafil—Liver function test abnormal—Carmustine—melanoma	0.00126	0.00437	CcSEcCtD
Vardenafil—Nervous system disorder—Vemurafenib—melanoma	0.00125	0.00432	CcSEcCtD
Vardenafil—Skin disorder—Vemurafenib—melanoma	0.00123	0.00428	CcSEcCtD
Vardenafil—Breast disorder—Temozolomide—melanoma	0.00119	0.00414	CcSEcCtD
Vardenafil—Acute coronary syndrome—Bleomycin—melanoma	0.00119	0.00412	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Temozolomide—melanoma	0.00119	0.00412	CcSEcCtD
Vardenafil—Hypotension—Vemurafenib—melanoma	0.00119	0.00411	CcSEcCtD
Vardenafil—Myocardial infarction—Bleomycin—melanoma	0.00118	0.0041	CcSEcCtD
Vardenafil—Dysphagia—Carmustine—melanoma	0.00118	0.00409	CcSEcCtD
Vardenafil—Influenza like illness—Docetaxel—melanoma	0.00117	0.00407	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Temozolomide—melanoma	0.00116	0.00404	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00116	0.00401	CcSEcCtD
Vardenafil—Haematuria—Bleomycin—melanoma	0.00115	0.00399	CcSEcCtD
Vardenafil—Dysphagia—Temozolomide—melanoma	0.00114	0.00396	CcSEcCtD
Vardenafil—Oesophagitis—Docetaxel—melanoma	0.00111	0.00383	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Vemurafenib—melanoma	0.0011	0.0038	CcSEcCtD
Vardenafil—Haemoglobin—Bleomycin—melanoma	0.00109	0.00377	CcSEcCtD
Vardenafil—Haemorrhage—Bleomycin—melanoma	0.00108	0.00375	CcSEcCtD
Vardenafil—Hypoaesthesia—Bleomycin—melanoma	0.00108	0.00374	CcSEcCtD
Vardenafil—Photosensitivity reaction—Temozolomide—melanoma	0.00104	0.00361	CcSEcCtD
Vardenafil—Infestation NOS—Temozolomide—melanoma	0.00102	0.00353	CcSEcCtD
Vardenafil—Infestation—Temozolomide—melanoma	0.00102	0.00353	CcSEcCtD
Vardenafil—Flushing—Bleomycin—melanoma	0.00101	0.00348	CcSEcCtD
Vardenafil—Pharyngitis—Dactinomycin—melanoma	0.001	0.00348	CcSEcCtD
Vardenafil—Hepatobiliary disease—Temozolomide—melanoma	0.000962	0.00334	CcSEcCtD
Vardenafil—Sinusitis—Temozolomide—melanoma	0.000955	0.00331	CcSEcCtD
Vardenafil—Haemoglobin—Carmustine—melanoma	0.00095	0.00329	CcSEcCtD
Vardenafil—Haemorrhage—Carmustine—melanoma	0.000945	0.00328	CcSEcCtD
Vardenafil—Erythema—Bleomycin—melanoma	0.000943	0.00327	CcSEcCtD
Vardenafil—Hypoaesthesia—Carmustine—melanoma	0.000941	0.00326	CcSEcCtD
Vardenafil—Hot flush—Docetaxel—melanoma	0.000939	0.00325	CcSEcCtD
Vardenafil—Flushing—Dactinomycin—melanoma	0.000937	0.00325	CcSEcCtD
Vardenafil—Hypersensitivity—Vemurafenib—melanoma	0.000936	0.00324	CcSEcCtD
Vardenafil—Menopausal symptoms—Docetaxel—melanoma	0.000931	0.00323	CcSEcCtD
Vardenafil—Connective tissue disorder—Carmustine—melanoma	0.000929	0.00322	CcSEcCtD
Vardenafil—Visual disturbance—Docetaxel—melanoma	0.000927	0.00321	CcSEcCtD
Vardenafil—Haemoglobin—Temozolomide—melanoma	0.000918	0.00318	CcSEcCtD
Vardenafil—Haemorrhage—Temozolomide—melanoma	0.000913	0.00317	CcSEcCtD
Vardenafil—Asthenia—Vemurafenib—melanoma	0.000911	0.00316	CcSEcCtD
Vardenafil—Visual impairment—Carmustine—melanoma	0.000911	0.00316	CcSEcCtD
Vardenafil—Hypoaesthesia—Temozolomide—melanoma	0.000909	0.00315	CcSEcCtD
Vardenafil—Pharyngitis—Temozolomide—melanoma	0.000907	0.00314	CcSEcCtD
Vardenafil—Urinary tract disorder—Temozolomide—melanoma	0.000902	0.00313	CcSEcCtD
Vardenafil—Pruritus—Vemurafenib—melanoma	0.000898	0.00311	CcSEcCtD
Vardenafil—Connective tissue disorder—Temozolomide—melanoma	0.000898	0.00311	CcSEcCtD
Vardenafil—Urethral disorder—Temozolomide—melanoma	0.000895	0.0031	CcSEcCtD
Vardenafil—Eye disorder—Carmustine—melanoma	0.000883	0.00306	CcSEcCtD
Vardenafil—Visual impairment—Temozolomide—melanoma	0.00088	0.00305	CcSEcCtD
Vardenafil—Erythema—Dactinomycin—melanoma	0.000879	0.00305	CcSEcCtD
Vardenafil—Flushing—Carmustine—melanoma	0.000877	0.00304	CcSEcCtD
Vardenafil—Ill-defined disorder—Bleomycin—melanoma	0.000875	0.00303	CcSEcCtD
Vardenafil—Diarrhoea—Vemurafenib—melanoma	0.000869	0.00301	CcSEcCtD
Vardenafil—Eye disorder—Temozolomide—melanoma	0.000854	0.00296	CcSEcCtD
Vardenafil—Tinnitus—Temozolomide—melanoma	0.000852	0.00295	CcSEcCtD
Vardenafil—Malaise—Bleomycin—melanoma	0.00085	0.00295	CcSEcCtD
Vardenafil—Cardiac disorder—Temozolomide—melanoma	0.000848	0.00294	CcSEcCtD
Vardenafil—Flushing—Temozolomide—melanoma	0.000848	0.00294	CcSEcCtD
Vardenafil—Dizziness—Vemurafenib—melanoma	0.00084	0.00291	CcSEcCtD
Vardenafil—Angiopathy—Temozolomide—melanoma	0.000829	0.00287	CcSEcCtD
Vardenafil—Mental disorder—Carmustine—melanoma	0.000828	0.00287	CcSEcCtD
Vardenafil—Immune system disorder—Temozolomide—melanoma	0.000825	0.00286	CcSEcCtD
Vardenafil—Mediastinal disorder—Temozolomide—melanoma	0.000823	0.00285	CcSEcCtD
Vardenafil—Erythema—Carmustine—melanoma	0.000823	0.00285	CcSEcCtD
Vardenafil—Ill-defined disorder—Dactinomycin—melanoma	0.000816	0.00283	CcSEcCtD
Vardenafil—Liver function test abnormal—Docetaxel—melanoma	0.000811	0.00281	CcSEcCtD
Vardenafil—Vomiting—Vemurafenib—melanoma	0.000807	0.0028	CcSEcCtD
Vardenafil—Myalgia—Bleomycin—melanoma	0.000803	0.00278	CcSEcCtD
Vardenafil—Chest pain—Bleomycin—melanoma	0.000803	0.00278	CcSEcCtD
Vardenafil—Abdominal pain upper—Docetaxel—melanoma	0.000802	0.00278	CcSEcCtD
Vardenafil—Orthostatic hypotension—Docetaxel—melanoma	0.000802	0.00278	CcSEcCtD
Vardenafil—Rash—Vemurafenib—melanoma	0.000801	0.00278	CcSEcCtD
Vardenafil—Mental disorder—Temozolomide—melanoma	0.0008	0.00277	CcSEcCtD
Vardenafil—Dermatitis—Vemurafenib—melanoma	0.0008	0.00277	CcSEcCtD
Vardenafil—Back pain—Carmustine—melanoma	0.000796	0.00276	CcSEcCtD
Vardenafil—Headache—Vemurafenib—melanoma	0.000796	0.00276	CcSEcCtD
Vardenafil—Erythema—Temozolomide—melanoma	0.000795	0.00276	CcSEcCtD
Vardenafil—Breast disorder—Docetaxel—melanoma	0.000794	0.00275	CcSEcCtD
Vardenafil—Discomfort—Bleomycin—melanoma	0.000793	0.00275	CcSEcCtD
Vardenafil—Malaise—Dactinomycin—melanoma	0.000793	0.00275	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000791	0.00274	CcSEcCtD
Vardenafil—Cramp muscle—Docetaxel—melanoma	0.000791	0.00274	CcSEcCtD
Vardenafil—Vision blurred—Carmustine—melanoma	0.000775	0.00269	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Docetaxel—melanoma	0.000774	0.00269	CcSEcCtD
Vardenafil—Anaphylactic shock—Bleomycin—melanoma	0.000769	0.00267	CcSEcCtD
Vardenafil—Back pain—Temozolomide—melanoma	0.000769	0.00267	CcSEcCtD
Vardenafil—Infection—Bleomycin—melanoma	0.000764	0.00265	CcSEcCtD
Vardenafil—Dysphagia—Docetaxel—melanoma	0.000759	0.00263	CcSEcCtD
Vardenafil—Nausea—Vemurafenib—melanoma	0.000754	0.00262	CcSEcCtD
Vardenafil—Vision blurred—Temozolomide—melanoma	0.000749	0.0026	CcSEcCtD
Vardenafil—Myalgia—Dactinomycin—melanoma	0.000749	0.0026	CcSEcCtD
Vardenafil—Discomfort—Dactinomycin—melanoma	0.00074	0.00256	CcSEcCtD
Vardenafil—Angina pectoris—Docetaxel—melanoma	0.000739	0.00256	CcSEcCtD
Vardenafil—Ill-defined disorder—Temozolomide—melanoma	0.000738	0.00256	CcSEcCtD
Vardenafil—Angioedema—Temozolomide—melanoma	0.000727	0.00252	CcSEcCtD
Vardenafil—Hypotension—Bleomycin—melanoma	0.000719	0.00249	CcSEcCtD
Vardenafil—Malaise—Temozolomide—melanoma	0.000717	0.00249	CcSEcCtD
Vardenafil—Vertigo—Temozolomide—melanoma	0.000714	0.00248	CcSEcCtD
Vardenafil—Convulsion—Carmustine—melanoma	0.000713	0.00247	CcSEcCtD
Vardenafil—Infection—Dactinomycin—melanoma	0.000713	0.00247	CcSEcCtD
Vardenafil—Palpitations—Temozolomide—melanoma	0.000703	0.00244	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Bleomycin—melanoma	0.000701	0.00243	CcSEcCtD
Vardenafil—Chest pain—Carmustine—melanoma	0.000701	0.00243	CcSEcCtD
Vardenafil—Myalgia—Carmustine—melanoma	0.000701	0.00243	CcSEcCtD
Vardenafil—Anxiety—Carmustine—melanoma	0.000698	0.00242	CcSEcCtD
Vardenafil—Paraesthesia—Bleomycin—melanoma	0.000691	0.0024	CcSEcCtD
Vardenafil—Convulsion—Temozolomide—melanoma	0.000689	0.00239	CcSEcCtD
Vardenafil—Dyspnoea—Bleomycin—melanoma	0.000686	0.00238	CcSEcCtD
Vardenafil—Myalgia—Temozolomide—melanoma	0.000677	0.00235	CcSEcCtD
Vardenafil—Arthralgia—Temozolomide—melanoma	0.000677	0.00235	CcSEcCtD
Vardenafil—Infestation NOS—Docetaxel—melanoma	0.000677	0.00235	CcSEcCtD
Vardenafil—Infestation—Docetaxel—melanoma	0.000677	0.00235	CcSEcCtD
Vardenafil—Anxiety—Temozolomide—melanoma	0.000675	0.00234	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000672	0.00233	CcSEcCtD
Vardenafil—Discomfort—Temozolomide—melanoma	0.000669	0.00232	CcSEcCtD
Vardenafil—Infection—Carmustine—melanoma	0.000667	0.00231	CcSEcCtD
Vardenafil—Acute coronary syndrome—Docetaxel—melanoma	0.000667	0.00231	CcSEcCtD
Vardenafil—Myocardial infarction—Docetaxel—melanoma	0.000663	0.0023	CcSEcCtD
Vardenafil—Dry mouth—Temozolomide—melanoma	0.000662	0.0023	CcSEcCtD
Vardenafil—Pain—Bleomycin—melanoma	0.000658	0.00228	CcSEcCtD
Vardenafil—Conjunctivitis—Docetaxel—melanoma	0.000658	0.00228	CcSEcCtD
Vardenafil—Tachycardia—Carmustine—melanoma	0.000655	0.00227	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000654	0.00227	CcSEcCtD
Vardenafil—Anaphylactic shock—Temozolomide—melanoma	0.000649	0.00225	CcSEcCtD
Vardenafil—Infection—Temozolomide—melanoma	0.000645	0.00224	CcSEcCtD
Vardenafil—Hepatobiliary disease—Docetaxel—melanoma	0.00064	0.00222	CcSEcCtD
Vardenafil—Epistaxis—Docetaxel—melanoma	0.000638	0.00221	CcSEcCtD
Vardenafil—Nervous system disorder—Temozolomide—melanoma	0.000636	0.00221	CcSEcCtD
Vardenafil—Feeling abnormal—Bleomycin—melanoma	0.000634	0.0022	CcSEcCtD
Vardenafil—Skin disorder—Temozolomide—melanoma	0.00063	0.00219	CcSEcCtD
Vardenafil—Hypotension—Carmustine—melanoma	0.000628	0.00218	CcSEcCtD
Vardenafil—Hyperhidrosis—Temozolomide—melanoma	0.000627	0.00218	CcSEcCtD
Vardenafil—Pain—Dactinomycin—melanoma	0.000614	0.00213	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Carmustine—melanoma	0.000612	0.00212	CcSEcCtD
Vardenafil—Haemoglobin—Docetaxel—melanoma	0.000611	0.00212	CcSEcCtD
Vardenafil—Rhinitis—Docetaxel—melanoma	0.000609	0.00211	CcSEcCtD
Vardenafil—Haemorrhage—Docetaxel—melanoma	0.000607	0.00211	CcSEcCtD
Vardenafil—Insomnia—Carmustine—melanoma	0.000607	0.00211	CcSEcCtD
Vardenafil—Hypoaesthesia—Docetaxel—melanoma	0.000604	0.0021	CcSEcCtD
Vardenafil—Paraesthesia—Carmustine—melanoma	0.000603	0.00209	CcSEcCtD
Vardenafil—Pharyngitis—Docetaxel—melanoma	0.000603	0.00209	CcSEcCtD
Vardenafil—Urinary tract disorder—Docetaxel—melanoma	0.0006	0.00208	CcSEcCtD
Vardenafil—Dyspnoea—Carmustine—melanoma	0.000599	0.00208	CcSEcCtD
Vardenafil—Somnolence—Carmustine—melanoma	0.000597	0.00207	CcSEcCtD
Vardenafil—Connective tissue disorder—Docetaxel—melanoma	0.000597	0.00207	CcSEcCtD
Vardenafil—Urethral disorder—Docetaxel—melanoma	0.000595	0.00206	CcSEcCtD
Vardenafil—Feeling abnormal—Dactinomycin—melanoma	0.000591	0.00205	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Temozolomide—melanoma	0.000591	0.00205	CcSEcCtD
Vardenafil—Insomnia—Temozolomide—melanoma	0.000587	0.00204	CcSEcCtD
Vardenafil—Gastrointestinal pain—Dactinomycin—melanoma	0.000587	0.00203	CcSEcCtD
Vardenafil—Visual impairment—Docetaxel—melanoma	0.000585	0.00203	CcSEcCtD
Vardenafil—Paraesthesia—Temozolomide—melanoma	0.000583	0.00202	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Carmustine—melanoma	0.00058	0.00201	CcSEcCtD
Vardenafil—Dyspnoea—Temozolomide—melanoma	0.000579	0.00201	CcSEcCtD
Vardenafil—Somnolence—Temozolomide—melanoma	0.000577	0.002	CcSEcCtD
Vardenafil—Pain—Carmustine—melanoma	0.000574	0.00199	CcSEcCtD
Vardenafil—Dyspepsia—Temozolomide—melanoma	0.000571	0.00198	CcSEcCtD
Vardenafil—Eye disorder—Docetaxel—melanoma	0.000568	0.00197	CcSEcCtD
Vardenafil—Abdominal pain—Dactinomycin—melanoma	0.000567	0.00197	CcSEcCtD
Vardenafil—Hypersensitivity—Bleomycin—melanoma	0.000567	0.00197	CcSEcCtD
Vardenafil—Flushing—Docetaxel—melanoma	0.000564	0.00195	CcSEcCtD
Vardenafil—Cardiac disorder—Docetaxel—melanoma	0.000564	0.00195	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Temozolomide—melanoma	0.00056	0.00194	CcSEcCtD
Vardenafil—Pain—Temozolomide—melanoma	0.000555	0.00192	CcSEcCtD
Vardenafil—Feeling abnormal—Carmustine—melanoma	0.000553	0.00192	CcSEcCtD
Vardenafil—Asthenia—Bleomycin—melanoma	0.000552	0.00191	CcSEcCtD
Vardenafil—Angiopathy—Docetaxel—melanoma	0.000551	0.00191	CcSEcCtD
Vardenafil—Gastrointestinal pain—Carmustine—melanoma	0.000549	0.0019	CcSEcCtD
Vardenafil—Immune system disorder—Docetaxel—melanoma	0.000549	0.0019	CcSEcCtD
Vardenafil—Mediastinal disorder—Docetaxel—melanoma	0.000547	0.0019	CcSEcCtD
Vardenafil—Pruritus—Bleomycin—melanoma	0.000544	0.00189	CcSEcCtD
Vardenafil—Feeling abnormal—Temozolomide—melanoma	0.000535	0.00185	CcSEcCtD
Vardenafil—Mental disorder—Docetaxel—melanoma	0.000532	0.00185	CcSEcCtD
Vardenafil—Abdominal pain—Carmustine—melanoma	0.000531	0.00184	CcSEcCtD
Vardenafil—Gastrointestinal pain—Temozolomide—melanoma	0.000531	0.00184	CcSEcCtD
Vardenafil—Erythema—Docetaxel—melanoma	0.000529	0.00183	CcSEcCtD
Vardenafil—Hypersensitivity—Dactinomycin—melanoma	0.000529	0.00183	CcSEcCtD
Vardenafil—Asthenia—Dactinomycin—melanoma	0.000515	0.00178	CcSEcCtD
Vardenafil—Abdominal pain—Temozolomide—melanoma	0.000513	0.00178	CcSEcCtD
Vardenafil—Back pain—Docetaxel—melanoma	0.000512	0.00177	CcSEcCtD
Vardenafil—Muscle spasms—Docetaxel—melanoma	0.000508	0.00176	CcSEcCtD
Vardenafil—Hypersensitivity—Carmustine—melanoma	0.000495	0.00172	CcSEcCtD
Vardenafil—Diarrhoea—Dactinomycin—melanoma	0.000491	0.0017	CcSEcCtD
Vardenafil—Vomiting—Bleomycin—melanoma	0.000489	0.0017	CcSEcCtD
Vardenafil—Rash—Bleomycin—melanoma	0.000485	0.00168	CcSEcCtD
Vardenafil—Dermatitis—Bleomycin—melanoma	0.000485	0.00168	CcSEcCtD
Vardenafil—Asthenia—Carmustine—melanoma	0.000482	0.00167	CcSEcCtD
Vardenafil—Hypersensitivity—Temozolomide—melanoma	0.000478	0.00166	CcSEcCtD
Vardenafil—Syncope—Docetaxel—melanoma	0.000474	0.00164	CcSEcCtD
Vardenafil—Palpitations—Docetaxel—melanoma	0.000467	0.00162	CcSEcCtD
Vardenafil—Asthenia—Temozolomide—melanoma	0.000466	0.00161	CcSEcCtD
Vardenafil—Loss of consciousness—Docetaxel—melanoma	0.000465	0.00161	CcSEcCtD
Vardenafil—Diarrhoea—Carmustine—melanoma	0.000459	0.00159	CcSEcCtD
Vardenafil—Pruritus—Temozolomide—melanoma	0.000459	0.00159	CcSEcCtD
Vardenafil—Convulsion—Docetaxel—melanoma	0.000458	0.00159	CcSEcCtD
Vardenafil—Nausea—Bleomycin—melanoma	0.000457	0.00158	CcSEcCtD
Vardenafil—Vomiting—Dactinomycin—melanoma	0.000456	0.00158	CcSEcCtD
Vardenafil—Rash—Dactinomycin—melanoma	0.000452	0.00157	CcSEcCtD
Vardenafil—Arthralgia—Docetaxel—melanoma	0.00045	0.00156	CcSEcCtD
Vardenafil—Myalgia—Docetaxel—melanoma	0.00045	0.00156	CcSEcCtD
Vardenafil—Chest pain—Docetaxel—melanoma	0.00045	0.00156	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000447	0.00155	CcSEcCtD
Vardenafil—Dizziness—Carmustine—melanoma	0.000444	0.00154	CcSEcCtD
Vardenafil—Diarrhoea—Temozolomide—melanoma	0.000444	0.00154	CcSEcCtD
Vardenafil—Dry mouth—Docetaxel—melanoma	0.00044	0.00153	CcSEcCtD
Vardenafil—Anaphylactic shock—Docetaxel—melanoma	0.000432	0.0015	CcSEcCtD
Vardenafil—Dizziness—Temozolomide—melanoma	0.000429	0.00149	CcSEcCtD
Vardenafil—Infection—Docetaxel—melanoma	0.000429	0.00149	CcSEcCtD
Vardenafil—Vomiting—Carmustine—melanoma	0.000427	0.00148	CcSEcCtD
Vardenafil—Nausea—Dactinomycin—melanoma	0.000426	0.00148	CcSEcCtD
Vardenafil—Shock—Docetaxel—melanoma	0.000425	0.00147	CcSEcCtD
Vardenafil—Rash—Carmustine—melanoma	0.000423	0.00147	CcSEcCtD
Vardenafil—Nervous system disorder—Docetaxel—melanoma	0.000423	0.00147	CcSEcCtD
Vardenafil—Dermatitis—Carmustine—melanoma	0.000423	0.00147	CcSEcCtD
Vardenafil—Tachycardia—Docetaxel—melanoma	0.000421	0.00146	CcSEcCtD
Vardenafil—Headache—Carmustine—melanoma	0.000421	0.00146	CcSEcCtD
Vardenafil—Skin disorder—Docetaxel—melanoma	0.000419	0.00145	CcSEcCtD
Vardenafil—Vomiting—Temozolomide—melanoma	0.000413	0.00143	CcSEcCtD
Vardenafil—Rash—Temozolomide—melanoma	0.000409	0.00142	CcSEcCtD
Vardenafil—Dermatitis—Temozolomide—melanoma	0.000409	0.00142	CcSEcCtD
Vardenafil—Headache—Temozolomide—melanoma	0.000407	0.00141	CcSEcCtD
Vardenafil—Hypotension—Docetaxel—melanoma	0.000403	0.0014	CcSEcCtD
Vardenafil—Nausea—Carmustine—melanoma	0.000399	0.00138	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Docetaxel—melanoma	0.000393	0.00136	CcSEcCtD
Vardenafil—Insomnia—Docetaxel—melanoma	0.00039	0.00135	CcSEcCtD
Vardenafil—Paraesthesia—Docetaxel—melanoma	0.000388	0.00134	CcSEcCtD
Vardenafil—Nausea—Temozolomide—melanoma	0.000385	0.00134	CcSEcCtD
Vardenafil—Dyspnoea—Docetaxel—melanoma	0.000385	0.00133	CcSEcCtD
Vardenafil—Somnolence—Docetaxel—melanoma	0.000384	0.00133	CcSEcCtD
Vardenafil—Dyspepsia—Docetaxel—melanoma	0.00038	0.00132	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Docetaxel—melanoma	0.000373	0.00129	CcSEcCtD
Vardenafil—Pain—Docetaxel—melanoma	0.000369	0.00128	CcSEcCtD
Vardenafil—Feeling abnormal—Docetaxel—melanoma	0.000356	0.00123	CcSEcCtD
Vardenafil—Gastrointestinal pain—Docetaxel—melanoma	0.000353	0.00122	CcSEcCtD
Vardenafil—Abdominal pain—Docetaxel—melanoma	0.000341	0.00118	CcSEcCtD
Vardenafil—Hypersensitivity—Docetaxel—melanoma	0.000318	0.0011	CcSEcCtD
Vardenafil—Asthenia—Docetaxel—melanoma	0.00031	0.00107	CcSEcCtD
Vardenafil—Pruritus—Docetaxel—melanoma	0.000305	0.00106	CcSEcCtD
Vardenafil—Diarrhoea—Docetaxel—melanoma	0.000295	0.00102	CcSEcCtD
Vardenafil—Dizziness—Docetaxel—melanoma	0.000285	0.00099	CcSEcCtD
Vardenafil—Vomiting—Docetaxel—melanoma	0.000274	0.000951	CcSEcCtD
Vardenafil—Rash—Docetaxel—melanoma	0.000272	0.000943	CcSEcCtD
Vardenafil—Dermatitis—Docetaxel—melanoma	0.000272	0.000943	CcSEcCtD
Vardenafil—Headache—Docetaxel—melanoma	0.00027	0.000937	CcSEcCtD
Vardenafil—Nausea—Docetaxel—melanoma	0.000256	0.000889	CcSEcCtD
Vardenafil—PDE1B—Disease—APC—melanoma	4.52e-05	0.000146	CbGpPWpGaD
Vardenafil—PDE1B—Disease—KIT—melanoma	4.52e-05	0.000146	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CASP3—melanoma	4.51e-05	0.000146	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—IL2—melanoma	4.51e-05	0.000146	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CDH1—melanoma	4.5e-05	0.000146	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CDKN2B—melanoma	4.49e-05	0.000145	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CDKN1B—melanoma	4.49e-05	0.000145	CbGpPWpGaD
Vardenafil—PDE1B—Disease—EGF—melanoma	4.46e-05	0.000144	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—AKT1—melanoma	4.44e-05	0.000144	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CASP3—melanoma	4.4e-05	0.000142	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CCND1—melanoma	4.39e-05	0.000142	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—IL2—melanoma	4.39e-05	0.000142	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—IL6—melanoma	4.37e-05	0.000141	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—PIK3CA—melanoma	4.36e-05	0.000141	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CTNNB1—melanoma	4.35e-05	0.000141	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CD86—melanoma	4.34e-05	0.000141	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—CXCL8—melanoma	4.34e-05	0.000141	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—MAP2K1—melanoma	4.33e-05	0.00014	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—EDN1—melanoma	4.31e-05	0.000139	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PIK3CD—melanoma	4.3e-05	0.000139	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CCND1—melanoma	4.28e-05	0.000139	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PIK3CA—melanoma	4.27e-05	0.000138	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—KRAS—melanoma	4.27e-05	0.000138	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MMP9—melanoma	4.26e-05	0.000138	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CDKN1A—melanoma	4.25e-05	0.000138	CbGpPWpGaD
Vardenafil—PDE1B—Disease—BRAF—melanoma	4.24e-05	0.000137	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PTEN—melanoma	4.24e-05	0.000137	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CTNNB1—melanoma	4.24e-05	0.000137	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NFKB1—melanoma	4.22e-05	0.000137	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—TP53—melanoma	4.22e-05	0.000136	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CSF2—melanoma	4.21e-05	0.000136	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—FGF1—melanoma	4.21e-05	0.000136	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—UGT2B10—melanoma	4.21e-05	0.000136	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—VEGFA—melanoma	4.19e-05	0.000136	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MMP9—melanoma	4.16e-05	0.000135	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—IL2—melanoma	4.15e-05	0.000134	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—STAT3—melanoma	4.15e-05	0.000134	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CDKN1A—melanoma	4.14e-05	0.000134	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—NRAS—melanoma	4.14e-05	0.000134	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PTEN—melanoma	4.13e-05	0.000134	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—E2F1—melanoma	4.12e-05	0.000133	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—FGF2—melanoma	4.12e-05	0.000133	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NFKB1—melanoma	4.11e-05	0.000133	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PIK3CB—melanoma	4.1e-05	0.000133	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PDGFRA—melanoma	4.08e-05	0.000132	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—ITGB3—melanoma	4.04e-05	0.000131	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PRKCA—melanoma	4.04e-05	0.000131	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—HRAS—melanoma	4.03e-05	0.00013	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—AKT1—melanoma	4.03e-05	0.00013	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MAP2K1—melanoma	4e-05	0.000129	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PLA2G6—melanoma	3.98e-05	0.000129	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PIK3CD—melanoma	3.97e-05	0.000129	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MAPK3—melanoma	3.96e-05	0.000128	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SPP1—melanoma	3.96e-05	0.000128	CbGpPWpGaD
Vardenafil—PDE6G—Disease—HRAS—melanoma	3.95e-05	0.000128	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MAP2K2—melanoma	3.95e-05	0.000128	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—CXCL8—melanoma	3.94e-05	0.000128	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—PIK3CA—melanoma	3.92e-05	0.000127	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—HS3ST5—melanoma	3.91e-05	0.000127	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—BCL2—melanoma	3.91e-05	0.000127	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IFNG—melanoma	3.87e-05	0.000125	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MYC—melanoma	3.85e-05	0.000125	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—MDM2—melanoma	3.85e-05	0.000125	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—VEGFA—melanoma	3.83e-05	0.000124	CbGpPWpGaD
Vardenafil—PDE1B—Disease—FGF2—melanoma	3.8e-05	0.000123	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—ERBB2—melanoma	3.8e-05	0.000123	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—STAT3—melanoma	3.79e-05	0.000123	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NRAS—melanoma	3.78e-05	0.000122	CbGpPWpGaD
Vardenafil—PDE6G—Disease—IL6—melanoma	3.78e-05	0.000122	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MAPK1—melanoma	3.77e-05	0.000122	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—EGFR—melanoma	3.77e-05	0.000122	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—IL2—melanoma	3.77e-05	0.000122	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TERT—melanoma	3.75e-05	0.000121	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PIK3CB—melanoma	3.75e-05	0.000121	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—RAC1—melanoma	3.74e-05	0.000121	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CD4—melanoma	3.74e-05	0.000121	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—VEGFA—melanoma	3.73e-05	0.000121	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—STAT3—melanoma	3.7e-05	0.00012	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NRAS—melanoma	3.69e-05	0.000119	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—HRAS—melanoma	3.63e-05	0.000117	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MAPK3—melanoma	3.62e-05	0.000117	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—HIF1A—melanoma	3.59e-05	0.000116	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—VCAN—melanoma	3.57e-05	0.000116	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—AKT1—melanoma	3.56e-05	0.000115	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—KRAS—melanoma	3.56e-05	0.000115	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MDM2—melanoma	3.56e-05	0.000115	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MAPK3—melanoma	3.53e-05	0.000114	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MYC—melanoma	3.52e-05	0.000114	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CDKN1B—melanoma	3.52e-05	0.000114	CbGpPWpGaD
Vardenafil—PDE1B—Disease—ERBB2—melanoma	3.51e-05	0.000113	CbGpPWpGaD
Vardenafil—PDE6G—Disease—AKT1—melanoma	3.49e-05	0.000113	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—IL6—melanoma	3.47e-05	0.000112	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PIK3CB—melanoma	3.46e-05	0.000112	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CD4—melanoma	3.45e-05	0.000112	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MAPK1—melanoma	3.45e-05	0.000112	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—EGFR—melanoma	3.45e-05	0.000112	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IL2—melanoma	3.44e-05	0.000111	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MYC—melanoma	3.43e-05	0.000111	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KDR—melanoma	3.43e-05	0.000111	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PTGS2—melanoma	3.43e-05	0.000111	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MAPK1—melanoma	3.36e-05	0.000109	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—EGFR—melanoma	3.36e-05	0.000109	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CTNNB1—melanoma	3.32e-05	0.000108	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—FN1—melanoma	3.3e-05	0.000107	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PIK3CA—melanoma	3.27e-05	0.000106	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—KRAS—melanoma	3.26e-05	0.000105	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CDKN1B—melanoma	3.25e-05	0.000105	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CDKN1A—melanoma	3.25e-05	0.000105	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PTEN—melanoma	3.24e-05	0.000105	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NOTCH1—melanoma	3.23e-05	0.000105	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—NFKB1—melanoma	3.22e-05	0.000104	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—AKT1—melanoma	3.2e-05	0.000104	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—KRAS—melanoma	3.17e-05	0.000103	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CD80—melanoma	3.17e-05	0.000103	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TP53—melanoma	3.16e-05	0.000102	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KIT—melanoma	3.16e-05	0.000102	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—APC—melanoma	3.16e-05	0.000102	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PIK3CG—melanoma	3.16e-05	0.000102	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—NRAS—melanoma	3.16e-05	0.000102	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—EGF—melanoma	3.13e-05	0.000101	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CTNNB1—melanoma	3.07e-05	9.93e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—MAPK3—melanoma	3.03e-05	9.8e-05	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—HRAS—melanoma	3.03e-05	9.79e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CYP17A1—melanoma	3.01e-05	9.76e-05	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CDKN1A—melanoma	3e-05	9.7e-05	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PIK3CA—melanoma	2.99e-05	9.68e-05	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PTEN—melanoma	2.99e-05	9.68e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—BRAF—melanoma	2.97e-05	9.62e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PLCB4—melanoma	2.96e-05	9.59e-05	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PIK3CA—melanoma	2.91e-05	9.43e-05	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—STAT3—melanoma	2.9e-05	9.38e-05	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—IL6—melanoma	2.9e-05	9.37e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IGF1—melanoma	2.9e-05	9.37e-05	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TP53—melanoma	2.89e-05	9.37e-05	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—NRAS—melanoma	2.89e-05	9.35e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—MAPK1—melanoma	2.88e-05	9.33e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—EGFR—melanoma	2.88e-05	9.33e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GNA11—melanoma	2.85e-05	9.21e-05	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TP53—melanoma	2.82e-05	9.13e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MAP2K1—melanoma	2.8e-05	9.06e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—SLC6A11—melanoma	2.79e-05	9.02e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PIP4K2A—melanoma	2.79e-05	9.02e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—FASN—melanoma	2.79e-05	9.02e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PIK3CD—melanoma	2.78e-05	9e-05	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—MAPK3—melanoma	2.77e-05	8.96e-05	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—HRAS—melanoma	2.77e-05	8.96e-05	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—PIK3CA—melanoma	2.75e-05	8.91e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—SLC5A5—melanoma	2.74e-05	8.87e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—KRAS—melanoma	2.72e-05	8.81e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—MTAP—melanoma	2.71e-05	8.77e-05	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—HRAS—melanoma	2.7e-05	8.73e-05	CbGpPWpGaD
Vardenafil—PDE1B—Disease—STAT3—melanoma	2.67e-05	8.66e-05	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—AKT1—melanoma	2.67e-05	8.65e-05	CbGpPWpGaD
Vardenafil—PDE1B—Disease—NRAS—melanoma	2.67e-05	8.63e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—FGF2—melanoma	2.66e-05	8.62e-05	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—IL6—melanoma	2.65e-05	8.57e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GNAQ—melanoma	2.65e-05	8.57e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CD44—melanoma	2.65e-05	8.57e-05	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—MAPK1—melanoma	2.63e-05	8.52e-05	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—EGFR—melanoma	2.63e-05	8.52e-05	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—IL6—melanoma	2.58e-05	8.35e-05	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MAPK3—melanoma	2.55e-05	8.27e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CYP1B1—melanoma	2.54e-05	8.21e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PIK3CA—melanoma	2.5e-05	8.09e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MDM2—melanoma	2.49e-05	8.06e-05	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—KRAS—melanoma	2.49e-05	8.05e-05	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MYC—melanoma	2.48e-05	8.04e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—ERBB2—melanoma	2.46e-05	7.95e-05	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—AKT1—melanoma	2.44e-05	7.91e-05	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MAPK1—melanoma	2.43e-05	7.87e-05	CbGpPWpGaD
Vardenafil—PDE1B—Disease—EGFR—melanoma	2.43e-05	7.87e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PIK3CB—melanoma	2.42e-05	7.84e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PHGDH—melanoma	2.42e-05	7.82e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—LUM—melanoma	2.42e-05	7.82e-05	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—AKT1—melanoma	2.38e-05	7.71e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—HPSE—melanoma	2.37e-05	7.67e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CXCL8—melanoma	2.33e-05	7.54e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CUBN—melanoma	2.32e-05	7.53e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—HRAS—melanoma	2.31e-05	7.49e-05	CbGpPWpGaD
Vardenafil—PDE1B—Disease—KRAS—melanoma	2.3e-05	7.43e-05	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PIK3CA—melanoma	2.28e-05	7.4e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CDKN1B—melanoma	2.27e-05	7.36e-05	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—AKT1—melanoma	2.25e-05	7.28e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CSPG4—melanoma	2.25e-05	7.27e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—SDHD—melanoma	2.25e-05	7.27e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—BSG—melanoma	2.25e-05	7.27e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CASP3—melanoma	2.23e-05	7.21e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IL2—melanoma	2.23e-05	7.2e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—IL6—melanoma	2.21e-05	7.17e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GPAM—melanoma	2.17e-05	7.04e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CCND1—melanoma	2.17e-05	7.02e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CTNNB1—melanoma	2.15e-05	6.95e-05	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HRAS—melanoma	2.11e-05	6.84e-05	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PIK3CA—melanoma	2.11e-05	6.83e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MMP9—melanoma	2.11e-05	6.82e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CDKN1A—melanoma	2.1e-05	6.79e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PTEN—melanoma	2.09e-05	6.78e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—ABCB1—melanoma	2.09e-05	6.76e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NFKB1—melanoma	2.08e-05	6.75e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—AKT1—melanoma	2.04e-05	6.61e-05	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IL6—melanoma	2.02e-05	6.55e-05	CbGpPWpGaD
Vardenafil—PDE1B—Disease—HRAS—melanoma	1.95e-05	6.32e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PRKCA—melanoma	1.92e-05	6.22e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—ERCC2—melanoma	1.91e-05	6.17e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—VEGFA—melanoma	1.89e-05	6.12e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—STAT3—melanoma	1.87e-05	6.06e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NRAS—melanoma	1.87e-05	6.05e-05	CbGpPWpGaD
Vardenafil—PDE1B—Disease—IL6—melanoma	1.87e-05	6.05e-05	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—AKT1—melanoma	1.87e-05	6.04e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PLA2G6—melanoma	1.85e-05	5.98e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MAPK3—melanoma	1.79e-05	5.79e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MYC—melanoma	1.74e-05	5.63e-05	CbGpPWpGaD
Vardenafil—PDE1B—Disease—AKT1—melanoma	1.72e-05	5.58e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MAPK1—melanoma	1.7e-05	5.51e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—EGFR—melanoma	1.7e-05	5.51e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—VCAN—melanoma	1.66e-05	5.38e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KRAS—melanoma	1.61e-05	5.2e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PIK3CG—melanoma	1.51e-05	4.87e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PIK3CA—melanoma	1.48e-05	4.78e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PPARG—melanoma	1.45e-05	4.7e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TP53—melanoma	1.43e-05	4.63e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CYP17A1—melanoma	1.4e-05	4.54e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—HRAS—melanoma	1.37e-05	4.42e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PIK3CD—melanoma	1.32e-05	4.29e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GNA11—melanoma	1.32e-05	4.28e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IL6—melanoma	1.31e-05	4.23e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—ALB—melanoma	1.31e-05	4.23e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—FASN—melanoma	1.29e-05	4.19e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—SLC5A5—melanoma	1.27e-05	4.12e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GNAQ—melanoma	1.23e-05	3.98e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CD44—melanoma	1.23e-05	3.98e-05	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—AKT1—melanoma	1.21e-05	3.91e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CYP1B1—melanoma	1.18e-05	3.82e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PIK3CB—melanoma	1.15e-05	3.74e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PTGS2—melanoma	1.14e-05	3.7e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PTEN—melanoma	9.97e-06	3.23e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—ABCB1—melanoma	9.71e-06	3.14e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PRKCA—melanoma	8.94e-06	2.89e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—ERCC2—melanoma	8.87e-06	2.87e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PIK3CA—melanoma	7.03e-06	2.28e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PIK3CG—melanoma	7e-06	2.27e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PPARG—melanoma	6.76e-06	2.19e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PIK3CD—melanoma	6.15e-06	1.99e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—ALB—melanoma	6.08e-06	1.97e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—AKT1—melanoma	5.75e-06	1.86e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PIK3CB—melanoma	5.36e-06	1.74e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PTGS2—melanoma	5.32e-06	1.72e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PTEN—melanoma	4.64e-06	1.5e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PIK3CA—melanoma	3.27e-06	1.06e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—AKT1—melanoma	2.67e-06	8.65e-06	CbGpPWpGaD
